Hyperkalemia is a condition where blood potassium levels rise above 5.0 mmol/L, potentially disrupting nerve and muscle function, especially in the heart. It arises from imbalances in potassium intake, distribution, or excretion.
Potassium is essential for normal cell signaling, particularly in nerves and muscles. When levels exceed 5.0 mmol/L, cells become less responsive to electrical impulses. This can lead to arrhythmias, muscle weakness, or cardiac arrest in severe cases. The kidneys normally regulate potassium by filtering excess into urine. When this system fails, hyperkalemia develops.
According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), about 1 in 10 adults with chronic kidney disease experience hyperkalemia. The American Society of Nephrology notes that even mild elevations above 5.5 mmol/L increase the risk of sudden cardiac death by 30% in patients with renal impairment.
Hyperkalemia results from three main physiological disruptions: increased potassium release from cells, reduced renal excretion, or shifts between fluid compartments. These mechanisms often overlap in clinical settings.
Cellular breakdown releases stored potassium into the bloodstream. Trauma, burns, or rhabdomyolysis (muscle breakdown) trigger this. A 2021 study in *Critical Care Medicine* found that 42% of trauma patients with acute kidney injury had hyperkalemia within 24 hours of admission due to massive tissue damage.
Impaired kidney function is the most common cause. The kidneys filter potassium through the distal tubules. When glomerular filtration rate drops below 30 mL/min/1.73m², potassium clearance declines sharply. Patients with stage 3b or higher chronic kidney disease have a 25% prevalence of hyperkalemia, per the KDIGO guidelines.
Several drugs interfere with potassium excretion by blocking aldosterone or affecting sodium-potassium exchange. Spironolactone, eplerenone, and triamterene are mineralocorticoid receptor antagonists that reduce potassium secretion in the collecting duct. ACE inhibitors and ARBs also impair potassium excretion by lowering angiotensin II, which reduces aldosterone.
A 2020 retrospective analysis in *JAMA Internal Medicine* showed that patients on ACE inhibitors had a 1.8-fold higher risk of developing hyperkalemia compared to those not on these drugs. Among diabetic patients on metformin and an ACE inhibitor, 17% developed potassium levels above 5.5 mmol/L during follow-up.
Endocrine disorders also contribute. Addison's disease leads to low cortisol and aldosterone, reducing potassium excretion. A patient with untreated Addison's may present with fatigue, hyperpigmentation, and serum potassium levels exceeding 6.0 mmol/L.
Many assume hyperkalemia stems solely from dietary excess. In reality, dietary potassium contributes minimally to blood levels unless renal function is severely compromised. The average adult consumes 3,500-4,700 mg/day, well within safe limits for healthy individuals.
Another misconception is that hyperkalemia always presents with symptoms. In fact, 60% of cases are asymptomatic until levels exceed 6.0 mmol/L. Symptoms like muscle weakness, tingling, or palpitations appear late. Electrocardiogram changes-peaked T waves, widened QRS complexes-are early signs, but not always detected without routine screening.
True hyperkalemia is diagnosed via serum potassium testing. A single elevated value requires confirmation. Pseudohyperkalemia-artificially high readings due to hemolysis during blood draw-occurs in 1 in 150 samples. Always check for clotting or tube handling errors when values are borderline.
Hyperkalemia is classified by severity and underlying cause. Acute cases develop rapidly, often within hours, while chronic cases persist over weeks or months.
| Type | Onset | Common Causes | Example Scenario |
|---|---|---|---|
| Acute | Minutes to hours | Medication overdose, tumor lysis syndrome, severe trauma | Post-cardiac arrest patient with potassium rising from 4.8 to 6.3 mmol/L in 90 minutes |
| Chronic | Days to weeks | Chronic kidney disease, uncontrolled diabetes, long-term medication use | Diabetic patient on lisinopril with potassium at 5.9 mmol/L for three months |
| Pseudohyperkalemia | Immediate | Hemolysis, thrombocytosis, leukocytosis | Sample drawn from a patient with platelets at 700,000/µL, yielding falsely high potassium |
One non-obvious factor: insulin deficiency. Insulin drives potassium into cells. In type 1 diabetes, lack of insulin causes potassium to remain extracellular. A patient with diabetic ketoacidosis may have a potassium level of 6.1 mmol/L despite total body potassium being normal.
A 62-year-old man presented with fatigue and irregular heartbeat. His initial labs showed potassium at 6.2 mmol/L. He was taking losartan for hypertension and had no known kidney issues. Further testing revealed an estimated glomerular filtration rate (eGFR) of 28 mL/min/1.73m²-indicating stage 3b chronic kidney disease.
His hyperkalemia resulted from impaired renal excretion due to reduced nephron function. Losartan, an ARB, further suppressed aldosterone. After discontinuing the medication and starting a low-potassium diet, his potassium dropped to 4.9 mmol/L within five days.
This case illustrates that hyperkalemia often signals underlying organ dysfunction rather than a standalone issue. Routine screening in patients on renin-angiotensin-aldosterone system (RAAS) blockers is recommended, per the American Heart Association.
When potassium levels exceed 6.0 mmol/L, immediate treatment is needed. Calcium gluconate stabilizes cardiac membranes, insulin and dextrose drive potassium into cells, and sodium bicarbonate can correct acidosis that worsens hyperkalemia. Dialysis is required for refractory cases.
Understanding the root cause prevents recurrence. For example, switching from an ARB to a calcium channel blocker may allow continued blood pressure control without risking potassium elevation.
Recognizing the multifactorial nature of hyperkalemia improves diagnosis and management. Early detection through regular monitoring in at-risk populations reduces hospitalization and mortality.